SecBot SecBot
15-12G ·Filed Jul 6, 2026

CNTA

Centessa Pharmaceuticals plc
BEARISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001193125-26-295685
Deregistration
Actionable Insight ▼ Bearish

Shares will move to the OTC or cease trading entirely as the company goes dark. Given only 5 holders of record, this is a definitive end to public market participation, any remaining CNTA equity is essentially illiquid. Traders should close any positions immediately; there is no future catalyst path that restores public reporting.

DirectionBearish
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its ordinary shares and American Depositary Shares under Section 12(g) of the Exchange Act, terminating its SEC reporting obligations. The filing follows a Nasdaq delisting notice (Form 25-NSE) filed June 24, 2026, confirming a complete exit from public markets with only 5 holders of record. This represents a terminal liquidity event for remaining shareholders who will lose all public company transparency and most secondary trading access.

Key Facts

  • Centessa Pharmaceuticals filed Form 15-12G to terminate registration under Section 12(g) of the Securities Exchange Act of 1934
  • Deregistration covers both Ordinary Shares and American Depositary Shares (ADSs)
  • Approximate number of holders of record as of certification date: 5
  • Filed concurrently with a Form 25-NSE (delisting notice) from June 24, 2026, confirming the securities were already being removed from Nasdaq
  • No securities remain registered; no other classes have a duty to file reports under Section 13(a) or 15(d)

Financial Impact

Complete loss of SEC reporting transparency; no public market liquidity for remaining shares; no financial figures disclosed in filing

public_company_statusliquiditytransparency

Risk Factors

  • Complete loss of SEC financial reporting creates information asymmetry for remaining shareholders
  • Illiquidity, no exchange listing means wide bid-ask spreads or no secondary market at all
  • Potential for zero return on remaining equity if no going-private transaction accompanies the deregistration

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
47% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0001193125-26-295685
Document: 0001193125-26-295685-index-headers.html0001193125-26-295685
Document: 0001193125-26-295685-index.html0001193125-26-295685
Document: 0001193125-26-295685.txt0001193125-26-295685

Track record

5 reports on CNTA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Jul 6, 202619w ago 15-12G Bearish 7/10 Viewing No price data
  2. Apr 17, 202630w ago PREM14A Bullish 9/10 Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
  3. Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
  4. Mar 13, 202635w ago Insider Cluster Bearish 7/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
  5. Mar 13, 202635w ago Insider Cluster Bearish 6/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026